Osteogenesis imperfecta in combination with Graves disease
Marina S. Sheremeta,
Ekaterina A. Pigarova,
Kristina S. Kulikova,
Irina M. Belovalova,
Anatoliy N. Tyulpakov,
Pavel O. Rumiantsev https://doi.org/10.14341/omet2017477-82
Abstract
Osteogenesis imperfecta (OI) – is a group of genetically disorders, which are charaterized by a disturbed bone formation. In turn, the excess of thyroid hormones in Graves' disease (GD) also posses a negative effect on bone tissue, thereby aggravating OI. That requires from the endocrinologist the most careful management of patients with the combination of these pathologies. In this article, we present a unique clinical case of a combination of GD and OI.
About the Authors
Marina S. SheremetaEndocrinology Research Centre
Russian Federation
PhD
Competing Interests:
No conflict of interests
Ekaterina A. Pigarova
Endocrinology Research Centre
Russian Federation
PhD
Competing Interests:
No conflict of interests
Kristina S. Kulikova
Endocrinology Research Centre
Russian Federation
PhD
Competing Interests:
No conflict of interests
Irina M. Belovalova
Endocrinology Research Centre
Russian Federation
PhD
Competing Interests:
No conflict of interests
Anatoliy N. Tyulpakov
Endocrinology Research Centre
Russian Federation
ScD, Professor
Competing Interests:
No conflict of interests
Pavel O. Rumiantsev
Endocrinology Research Centre
Russian Federation
ScD
Competing Interests:
No conflict of interests
References
1. Bassett JHD, Williams GR. Role of Thyroid Hormones in Skeletal Development and Bone Maintenance. Endocr Rev. 2016;37(2):135-187. doi: 10.1210/er.2015-1106.
2. Lee HJ, Li CW, Hammerstad SS, et al. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J Autoimmun. 2015;64:82-90. doi: 10.1016/j.jaut.2015.07.009.
3. Benvenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. Reviews in Endocrine and Metabolic Disorders. 2016;17(4):485-498. doi: 10.1007/s11154-016-9363-2.
4. Chu M-L, Williams CJ, Pepe G, et al. Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta. Nature. 1983;304(5921):78-80. doi: 10.1038/304078a0.
5. Le.ac.uk [Internet]. Osteogenesisimperfecta& Ehlers-Danlos syndrome variant databases [updated 2017Jun27; cited 2017Jun27]. Available from: http://www.le.ac.uk/ge/collagen/
6. Willing MC, Deschenes SP, Slayton RL, Roberts EJ. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet. 1996;59(4):799-809.
7. Cropp GJ, Myers DN. Physiological evidence of hypermetabolism in osteogenesisimperfecta. Pediatrics. 1972;49(3):375-391.
8. Diegidio P, Kolok D, Brown W, Camps JI. Papillary thyroid cancer in identical adolescent twins with osteogenesis imperfecta and Hashimoto's thyroiditis: is there a genetic link?Am Surg. 2014;80(9):849-850.
9. Chen K, Xie Y, Zhao L, Mo Z. Hyperthyroidism-associated hypercalcemic crisis: A case report and review of the literature. Medicine (Baltimore). 2017;96(4):e6017. doi: 10.1097/MD.0000000000006017.
10. Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. The skeletal consequences of thyrotoxicosis. J Endocrinol. 2012;213(3):209-221. doi: 10.1530/JOE-12-0059.
11. Hoyer-Kuhn H, Franklin J, Allo G, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16(1):24-32..
12. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med. 2006;354(8):821-831. doi: 10.1056/NEJMoa044459.
13. Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. Journal of Multidisciplinary Healthcare. 2017;Volume 10:145-155. doi: 10.2147/jmdh.s113483.
14. Hoyer-Kuhn H, Semler O, Schoenau E. Effect of Denosumab on the Growing Skeleton in Osteogenesis Imperfecta. J Clin Endocr Metab. 2014;99(11):3954-3955. doi: 10.1210/jc.2014-3072.
Supplementary files
|
|
1. Рис. 1. Сцинтиграфия щитовидной железы с Tc99. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(1MB)
|
Indexing metadata ▾ | |
|
|
2. Рис. 2. Синий оттенок склер пациентки. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(631KB)
|
Indexing metadata ▾ | |
|
|
3. Рис. 3. Денситометрия позвоночника от пациентки. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(1MB)
|
Indexing metadata ▾ | |
|
|
4. Рис. 4. Оценка трабекулярного костного индекса пациентки. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(326KB)
|
Indexing metadata ▾ | |
|
|
5. Рис. 5. Область шеи до проведения радиойодтерапии. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(67KB)
|
Indexing metadata ▾ | |
|
|
6. Рис. 6. Область шеи через 3 мес после радиойодтерапии. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(279KB)
|
Indexing metadata ▾ | |
Review
For citations:
Sheremeta M.S., Pigarova E.A., Kulikova K.S., Belovalova I.M., Tyulpakov A.N., Rumiantsev P.O. Osteogenesis imperfecta in combination with Graves disease. Obesity and metabolism. 2017;14(4):77-82. (In Russ.) https://doi.org/10.14341/omet2017477-82
Views:
2254
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
